Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2021 financial results, revealing a revenue of $3.4 million, an 8% increase from Q1 2020. Gross profit rose by 11% to $2.7 million with a gross margin of 78%. However, net loss increased to $3.4 million from $2.6 million year-over-year. The company bolstered its finances with a follow-on offering generating $27.6 million in May. Recent developments include the launch of AireO2 software and VivoScore home testing services, along with the opening of Pneusomnia Centers aimed at enhancing treatment options for sleep disorders.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its first-quarter financial results for 2021 on May 17, 2021, after market close. A conference call is scheduled for the same day at 5:00 PM ET, where the company will discuss its financial performance and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA). Their Vivos System has been effective for over 15,000 patients worldwide through customized oral appliances.
Vivos Therapeutics, Inc. (VVOS) announced the closing of its public offering of 4,600,000 shares of common stock, including 600,000 additional shares underwriters purchased. The offering price was set at $6.00 per share, leading to gross proceeds of $27.6 million before expenses. Roth Capital Partners served as the sole book-running manager, while National Securities Corporation and Craig-Hallum Capital Group were co-managers. The SEC declared the registration statement effective on May 6, 2021, and the final prospectus was filed on May 10, 2021.
Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced the pricing of a follow-on public offering of 4,000,000 shares of its common stock at $6.00 per share, aiming for gross proceeds of $24 million before deductions. The offering includes a 45-day option for underwriters to buy an additional 600,000 shares. Roth Capital Partners is the sole book-running manager for the offering. The Securities and Exchange Commission (SEC) has declared effective registration statements, and a final prospectus will be filed with the SEC. Investors are encouraged to read the prospectus for complete information.
Vivos Therapeutics (NASDAQ: VVOS) announced the appointment of Dr. Mimi Guarneri as Medical Director of Clinical Education, effective April 1, 2021. Dr. Guarneri is a renowned Integrative Cardiologist, board-certified in multiple specialties, and a founder of The Academy of Integrative Health and Medicine. Her role will focus on promoting the Vivos Medical Integration Division, leveraging her expertise to enhance physician awareness of Vivos’ innovative treatments for obstructive sleep apnea (OSA). The company aims to improve patient outcomes with its non-invasive Vivos System, already utilized by over 1,200 dentists worldwide.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Emerging Growth Conference on April 14, 2021, at 9:00 am EDT. The presentation will be led by CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew.
Investors can register for a free spectator pass. Vivos specializes in treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), offering the innovative Vivos System, which is a non-invasive solution already benefiting over 15,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) has announced the launch of MyoCorrect, a telemedicine service offering orofacial myofunctional therapy (OMT) to enhance the treatment of obstructive sleep apnea (OSA). This initiative aims to provide Vivos-trained providers with greater access to OMT, expected to drive additional revenue through increased Vivos System cases and service fees. Vivos anticipates that MyoCorrect will strengthen its competitive positioning in the OSA market, as trained dentists report numerous benefits from integrating OMT into their treatment protocols.
Vivos Therapeutics reported a 15% revenue increase for full year 2020, reaching $13.1 million, up from $11.4 million in 2019. The fourth quarter revenue hit $3.3 million with a gross profit of $2.7 million, marking an 81% gross margin. Despite a net loss of $12.1 million for the full year, the company surpassed 15,000 cases treated. Financial resilience was aided by a $21.6 million IPO in December 2020. New product launches, including AireO2 and VivoScore, are expected to enhance their market position.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 11:40 am Eastern Time. The conference runs from March 24-25, 2021. Key presenters include CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), using non-invasive methods. Interested investors can register for a free spectator pass via the provided link.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced plans to release its financial results for Q4 and the full year ended December 31, 2020, after market close on March 25, 2021. The company will hold a conference call at 5:00 p.m. ET to discuss the results and its growth strategy. Vivos aims to provide innovative treatments for sleep-disordered breathing, specifically mild-to-moderate obstructive sleep apnea (OSA), with its Vivos System oral appliances, proven effective in over 15,000 patients. The company is committed to growth through improved treatment technologies.
